San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
We're in the final days of our fall fundraiser. Will you help us ask the tough questions about the issues that matter to San Diego?